A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Induced Skin Toxicities in Patients With Metastatic Lung Cancer

(2016) Barbara Melosky et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of egfr tki–induced dermatologic adverse events

(2015) B. Melosky et al.   Current Oncology

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

(2014) V. Hirsh et al.   Current Oncology

Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer

(2014) Tony Mok et al.   Future Oncology

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

(2010) Mario E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes

(2008) Aminah Jatoi et al.   CANCER